WARNER-LAMBERT TROGLITAZONE ORAL ANTIDIABETIC IS IN PHASE III
Executive Summary
WARNER-LAMBERT TROGLITAZONE ORAL ANTIDIABETIC IS IN PHASE III with an NDA filing scheduled for 1996, Parke-Davis Research Chairman Ron Cresswell told an April 15 meeting with securities analysts in New York City. Phase II data presented by Cresswell showed that a once-daily 400 mg dose lowered glucose and triglyceride levels during the trial.